Company Overview of Protea Biosciences Group, Inc
Protea Biosciences Group, Inc., molecular information company, develops and commercializes proprietary life science technologies, products, and services to identify the molecules that are produced by living cells and various life forms. The company provides molecular information services for the identification of small and large molecules; and tissue analytics services to create tissue-based molecular profiles. It also offers laser ablation electrospray ionization, a bioanalytical instrument platform that enables the identification of proteins, lipids, and metabolites in tissue, cells, and biofluids, such as serum and urine with minimal or without any sample preparation prior to analysis. It...
955 Hartman Run Road
Morgantown, WV 26507
Founded in 2001
Key Executives for Protea Biosciences Group, Inc
Chairman, Chief Executive Officer and President
Total Annual Compensation: $240.0K
Chief Financial Officer
Total Annual Compensation: $145.6K
Vice President of Operations
Total Annual Compensation: $210.0K
Chief Science Officer and Vice President of Research & Development
Total Annual Compensation: $153.9K
Vice President of Corporate Finance and Development
Total Annual Compensation: $131.0K
Compensation as of Fiscal Year 2014.
Protea Biosciences Group, Inc Key Developments
Protea Biosciences Group, Inc Announces Board Appointments
Apr 24 15
Effective April 17, 2015, Maged Shenouda and Patrick Gallagher were appointed by the board of directors of Protea Biosciences Group Inc. to serve as directors to fill existing vacancies on the Board. Maged Shenouda has over 25 years of experience in the pharmaceutical and securities industries. Most recently, Mr. Shenouda was the Head of Business Development and Licensing at Retrophin Inc. Patrick Gallagher, CFA, is an accomplished Capital Markets executive, advisor and investor with a distinguished record of success in both the public and private markets with a focus on healthcare, agriculture and industrials. He is a Managing Director and Head of Institutional Sales for Laidlaw & Company (UK) Ltd. Mr. Gallagher sits on the board of directors for BioSig Technologies Inc.
Protea Biosciences Group, Inc. Announces Board Resignations
Mar 31 15
On March 25, 2015, Andrew Zulauf resigned as a Director of Protea Biosciences Group Inc. On March 31, 2015, Roderick Jackson resigned as a Director of the company.
Protea Biosciences Group, Inc Auditor Raises 'Going Concern' Doubt
Feb 13 15
Protea Biosciences Group, Inc filed its 10-K on Feb 13, 2015 for the period ending Dec 31, 2014. In this report its auditor, Schneider Downs & Co., Inc., gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 6, 2015
October 31, 2014